BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $104.00 at The Goldman Sachs Group
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price target cut by The Goldman Sachs Group from $124.00 to $104.00 in a research report sent to investors on Monday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. Other research analysts have also issued reports about the company. Oppenheimer raised BioMarin Pharmaceutical […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price target cut by The Goldman Sachs Group from $124.00 to $104.00 in a research report sent to investors on Monday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. Other research analysts have also issued reports about the company. Oppenheimer raised BioMarin Pharmaceutical […]
